ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 116 filers reported holding ACCELERON PHARMA INC in Q2 2015. The put-call ratio across all filers is 1.90 and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $3,796,000 | -22.1% | 148,729 | +10.4% | 0.00% | -33.3% |
| Q3 2016 | $4,873,000 | +6.7% | 134,664 | +0.2% | 0.01% | 0.0% |
| Q2 2016 | $4,569,000 | +47.0% | 134,458 | +14.2% | 0.01% | +50.0% |
| Q1 2016 | $3,108,000 | -39.0% | 117,762 | +12.6% | 0.00% | -42.9% |
| Q4 2015 | $5,099,000 | +96.3% | 104,579 | +0.2% | 0.01% | +75.0% |
| Q3 2015 | $2,598,000 | -21.2% | 104,324 | +0.2% | 0.00% | 0.0% |
| Q2 2015 | $3,296,000 | +17.7% | 104,163 | +41.6% | 0.00% | 0.0% |
| Q1 2015 | $2,801,000 | +1.1% | 73,586 | +3.5% | 0.00% | 0.0% |
| Q4 2014 | $2,770,000 | +60.7% | 71,103 | +24.7% | 0.00% | +100.0% |
| Q3 2014 | $1,724,000 | -10.7% | 57,014 | +0.3% | 0.00% | -33.3% |
| Q2 2014 | $1,930,000 | +174.1% | 56,822 | +178.5% | 0.00% | +200.0% |
| Q1 2014 | $704,000 | +5.4% | 20,406 | +21.0% | 0.00% | 0.0% |
| Q4 2013 | $668,000 | – | 16,869 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |